Phase 4 N=71 Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?
Sickle Cell Anemia Crisis
Primary: Cumulative Opioid Dosing — .2; .2 mg/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
Bipolar Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -39.24 Percent change in MADRS from baseline
Phase 4 N=757 FLUAD® vs. Fluzone® High-Dose Study
Pain · Quality of Life · Injection Site Reaction
Primary: Number of Participants With Injection-Site Pain in Arm That Was Vaccinated, Population 1 — 297; 282; 69; 73 Participants
Phase 4 N=99 Three New Ideas to Protect Special Forces From the Stress of High Altitude
Mountain Sickness
Primary: Change in Environmental Symptoms Questionnaire at High Altitude — 0.132; 0.122; 0.080; 0.069 score on a scale
Phase 4 N=28 Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
Pharmacokinetics · Epinephrine · Albuterol
Primary: C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine — 240.8; 704.8; 599.8 pg/mL
Phase 4 N=10 Ramelteon for Treatment of Insomnia in Cirrhosis
Cirrhosis
Primary: Sleep Quality Evaluation — 4.63; 11.75 score on a scale
Phase 4 N=84 Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
Cardiovascular Diseases
Primary: Change in Left Ventricle-end Systolic Volume (ESV) — -26.6; -0.5 ml
Phase 4 N=49 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Macular Degeneration · Wet Macular Degeneration
Primary: Anatomic Response
Phase 4 N=22 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
Allergic Rhinitis · Allergic Conjunctivitis
Primary: Change in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16) — -0.7; 0.3; -2.8; 0.9 units on a scale
Phase 4 N=654 Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar
Acute Pain
Primary: TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose) — 13.0; 9.2; 1.9 5-point Verbal Rating Scale
Phase 4 N=60 Comparison of Obturator Nerve Blockade and Neuromuscular Blockade
Cancer of Bladder
Primary: Number of Patients With Incidence of Intraoperative Adductor Spasm — 1; 5 Participants
Phase 4 N=50 The Effect of Platelet Rich Plasma (PRP) on Post Operative Pain in Anterior Cruciate Ligament Reconstruction
Post Operative Pain
Primary: Anterior Knee Pain — 2.4; 1.9 units on a scale — p=0.55
Phase 4 N=17 Xyrem and Brain Dopamine in Narcolepsy
Narcolepsy With Cataplexy · Healthy Controls
Primary: [C-11]Raclopride BPND at 1 Hour Post Xyrem — 2.94; 3.01; 3.80; 3.70 BPND (Binding Potential) — p=0.31
Phase 4 N=120 Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach
Cervical Radiculopathy
Primary: The Percentage of Participants With Reduction of 50% or More of Neck and Arm Pain NRS Score — 49.1; 68.5 percentage of participants
Phase 4 N=24 Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses
Healthy Human Volunteers
Primary: Tolerance to Cutaneous Electrical Current — 26.6; 27.1 mA